• Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules

  NCT05871437

  Not yet recruitingInterventionalPhase 4Updated Sep 8, 2025
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

  NCT04790305

  RecruitingInterventionalPhase 4Updated Jun 27, 2024
• Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer

  NCT06387368

  Not yet recruitingInterventionalPhase 4Updated Apr 29, 2024
• The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

  NCT06368063

  RecruitingInterventionalPhase 4Updated May 8, 2024
• Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

  NCT05673824

  CompletedInterventionalPhase 2Updated Feb 9, 2026
• Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy

  NCT06090994

  RecruitingInterventionalPhase 4Updated May 7, 2025

ClinicalTrials.gov ID

NCT05860907

Lead Sponsor

Fudan UniversityOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

384Estimated

Last Update Posted

Sep 26, 2023Actual

Start Date

Oct 2023Estimated

Primary Completion Date

Oct 2025Estimated

Completion Date

Oct 2027Estimated

Official Title

A Multicenter, Open-label, Randomized, Controlled, Prospective Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Brief Summary

This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.

Detailed Description

This study used a blank control design and included at least 384 subjects. The experimental group and control group were randomized in a 2:1 ratio (at least 256 subjects in the experimental group and at least 128 subjects in the control group). Patients in the experimental group were treated with Huaier Granules (10g/dose, 3 times/day), while undergoing routine diagnosis and treatment; The control group received routine diagnosis and treatment, but did not take Huaier granules until the subjects experienced disease progression or intolerance.

• Breast Cancer Stage IV

• Huaier Granule

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• 18 years old ≤ age ≤ 75, regardless of gender.
• For breast cancer patients who are clinically or pathologically diagnosed as non visceral metastasis, if the patient has only local recurrence or metastasis, the clinician judges that it is not suitable or refuses to use local treatment with radical intensity, such as surgical resection or radiotherapy.
• Prior to enrollment, no more than first-line chemotherapy/endocrine therapy/targeted therapy/immunotherapy were allowed;If the patient has previously received first-line therapy, the outcome of treatment should be clinically assessed as disease progression or intolerance.
• There is at least one measurable lesion that meets the RECIST 1.1 standard, or only bone metastases (including osteolytic lesions or mixed lesions).
• The liver and kidney functions meet the following conditions: AST and ALT<3 ULN, total bilirubin ≤ 2 ULN, and blood creatinine<1.5 ULN.
• Other laboratory tests meet the following requirements: Hb ≥ 9g/dl, platelet count ≥ 60 × 10^9/L, absolute neutrophil count>1.0 × 10^9/L.
• Expected survival time ≥ 12 weeks.
• The patient's ECOG physical state score is 0 or 1.
• The subjects participated in the study voluntarily and signed an informed consent form.

Exclusion Criteria:

• Any other malignancies diagnosed within 5 years prior to enrollment, except those with a low risk of metastasis and death (5-year survival > 90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.
• There is visceral metastasis of breast cancer.
• Patients with advanced (local recurrence or metastasis) breast cancer who plan to receive radical local treatment.
• Serious infections (CTCAE>Level 2) have occurred within 4 weeks prior to enrollment, such as severe pneumonia, bacteremia, infection complications that require hospitalization; Symptoms and signs of infection or the need for oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, except for prophylactic use of antibiotics.
• Suffering from severe acute and chronic diseases.
• Suffering from severe diabetes whose blood sugar cannot be effectively controlled.
• Patients who cannot take oral medication or are allergic to the ingredients of Huaier granules.
• Drug abusers, or those who suffer from psychological or mental illnesses that may interfere with research compliance.
• Pregnant or lactating women.
• The researcher believes that it is not suitable to participate in this study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Fudan UniversityOTHER

Collaborators

LinkDoc Technology (Beijing) Co. Ltd.INDUSTRY

Huazhong University of Science and TechnologyOTHER

+8613906500190

+8613906768336